Boston Scientific Corporation's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-28. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $5,138 million (+1.4% vs a year earlier) |
| Diluted EPS (GAAP) | $0.40 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $0.73 |
| Full-year guidance | Stated (no change given) |
Guidance
Now estimates 2026 net sales growth ~4.25% reported (~3.75% organic), adjusted EPS $3.16–$3.18; Q4 sales down 1%–3%, adjusted EPS $0.77–$0.79.
Why this label: 'Now estimates' FY2026 sales growth ~4.25% and adjusted EPS $3.16-$3.18; no prior figures or direction words; not called initial.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| net sales growth | FY2026 | ~4.25% reported; ~3.75% organic | not stated |
| adjusted EPS | FY2026 | $3.16–$3.18 | not stated |
Next-quarter outlook:
| Metric | Period | Range |
|---|---|---|
| net sales growth (reported and organic) | Q4 2026 | decline of ~1.0%–3.0% |
| adjusted EPS | Q4 2026 | $0.77–$0.79 |
From the release
Revenue: "Net Sales · $ · 5,138 · $ · 5,065 · 1.5 · %"
Earnings per share: "Reported GAAP net income attributable to Boston Scientific common stockholders of $0.40 per share, and achieved adjusted EPS of $0.73 per share."
net sales growth: "The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis."
adjusted EPS: "The company now estimates adjusted EPS, excluding certain charges (credits), of $3.16 to $3.18."
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Net sales grew 1.5%; company projects Q4 net sales decline of 1% to 3%.
Source
Boston Scientific Corporation earnings release (SEC filing), accession 0000885725-26-000066, filed 2026-10-28.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.